Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial.

Øie LR, Wergeland T, Salvesen Ø, Gravdahl GRB, Aschehoug I, Gulati S, Bj Rk MH, Lundqvist C, Alstadhaug KBR, Winsvold BS, Aamodt AH, Larsen IC, B E MG, Braschinsky M, Müller B, Vetvik KGT, Müller KI, Aaseth K, Khanevski AN, Øvrevik AB, Vegrim HM, Lindroos J, Eid K, Engstrand H, Bezgal B, Larsen MB, Østhus JHG, Stovner LJ, Tronvik E

Open source

DOI: 10.1016/s1474-4422(25)00269-8
Published: 2025 Oct
Container: The Lancet. Neurology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1474-4422-25-00269-8,
  title = {Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial.},
  author = {Øie LR and Wergeland T and Salvesen Ø and Gravdahl GRB and Aschehoug I and Gulati S and Bj Rk MH and Lundqvist C and Alstadhaug KBR and Winsvold BS and Aamodt AH and Larsen IC and B E MG and Braschinsky M and Müller B and Vetvik KGT and Müller KI and Aaseth K and Khanevski AN and Øvrevik AB and Vegrim HM and Lindroos J and Eid K and Engstrand H and Bezgal B and Larsen MB and Østhus JHG and Stovner LJ and Tronvik E},
  year = {2025},
  journal = {The Lancet. Neurology},
  doi = {10.1016/s1474-4422(25)00269-8},
  url = {https://doi.org/10.1016/s1474-4422(25)00269-8}
}

RIS

TY  - JOUR
TI  - Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial.
AU  - Øie LR
AU  - Wergeland T
AU  - Salvesen Ø
AU  - Gravdahl GRB
AU  - Aschehoug I
AU  - Gulati S
AU  - Bj Rk MH
AU  - Lundqvist C
AU  - Alstadhaug KBR
AU  - Winsvold BS
AU  - Aamodt AH
AU  - Larsen IC
AU  - B E MG
AU  - Braschinsky M
AU  - Müller B
AU  - Vetvik KGT
AU  - Müller KI
AU  - Aaseth K
AU  - Khanevski AN
AU  - Øvrevik AB
AU  - Vegrim HM
AU  - Lindroos J
AU  - Eid K
AU  - Engstrand H
AU  - Bezgal B
AU  - Larsen MB
AU  - Østhus JHG
AU  - Stovner LJ
AU  - Tronvik E
PY  - 2025
JO  - The Lancet. Neurology
DO  - 10.1016/s1474-4422(25)00269-8
UR  - https://doi.org/10.1016/s1474-4422(25)00269-8
ER  -

APA

LR, Ø., T, W., Ø, S., GRB, G., I, A., S, G., MH, B. R., C, L., KBR, A., BS, W., AH, A., IC, L., MG, B. E., M, B., B, M., KGT, V., KI, M., K, A., AN, K., AB, Ø., HM, V., J, L., K, E., H, E., B, B., MB, L., JHG, Ø., LJ, S., & E, T. (2025). Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial.. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(25)00269-8

Source records

pubmed · retrieved 2026-09-26T08:06:49.686Z